RELATIONSHIP BETWEEN KI-67 EXPRESSION AND CLINICAL OUTCOME IN BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPY
Objective To investigate the association of expression of Ki-67 with clinical effectiveness in breast cancer after neoadjuvant chemotherapy (NC).Methods One hundred and twelve female patients with stage Ⅱ-Ⅲ breast cancer were selected,and given a neoadjuvant chemotherapy before surgery.Samples were taken using EnCor vacuum assisted biopsy instrument,the expression of Ki-67-before and after NC-was detected employing immunohistochemistry,the association of Ki-67 with clinical efficacy was analyzed.Results Before NC,the high expression rate of Ki-67 was 80.4%,and the low of that was 19.6%;after NC,the high expression of Ki-67 was 26.8%,and the low of that was 73.2%,the differences in Ki-67 expression rates-before and after NC-were statistically significant (x2 =64.62,P<0.05).The clinical effective rate for NC was 45.5%,and the clinical benefit rate was 84.8%.Patients with high expression of Ki-67 were sensitive to NC,and the clinical efficacy was better in those with decline of Ki-67 after NC,and the efficacy was poor for those with no changes of Ki 67 after NC or Ki-67 raised from low to high,the changes of Ki-67 expression were related to clinical effectiveness (x2=25.153,P<0.05).Conclusion Ki-67 is likely to become a bioindicator in evaluation of neoadjuvant chemotherapy in breast cancer,which can predict the prognosis of the cancer after this kind of treatment.
breast neoplasmschemoradiotherapy, adjuvantKi-67 antigentreatment outcome